Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
Research on immunization reported by scientists at Centers for Disease Control and Prevention
September 24th, 2008
Research findings, 'The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination,' are discussed in a new report. According to recent research from the United States, "We estimated the health and economic benefits of preventing recurrent respiratory papillomatosis (RRP) through quadrivalent human papillomavirus (HPV) vaccination. We applied a simple mathematical model to estimate the averted costs and quality-adjusted life years (QALYs) saved by preventing RRP in children whose mothers had been vaccinated at age 12 years." "Under base case assumptions, the prevention of RRP would...
Source: Vaccine Weekly (2008-09-24)
|
